Obstetrics & Gynecology Doctors in Shawnee, OK Accepting Medicare

7 Obstetrics & Gynecology doctors found. Showing 1 - 7

Elise Eckhardt Slaybaugh, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3315 Kethley Rd, Shawnee, OK 74804 Phone: 405-273-5801    Fax: 405-878-3794

Dr. Paul Douglas Jennings, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3315 Kethley Rd, Shawnee, OK 74804 Phone: 405-273-5801    Fax: 405-878-3814

Lila Nevrekar, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 6 Castle Creek Place, Shawnee, OK 74804 Phone: 405-275-4987    Fax: 405-273-4879

Shawnaree L Lee, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4651 N Harrison St, Shawnee, OK 74804 Phone: 405-395-5655    Fax: 405-395-5654

Dr. Darin Craig Sparkman, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3315 Kethley Rd, Shawnee, OK 74804 Phone: 405-273-5801    Fax: 405-878-3794

Lauren E Floyd, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 4651 N Harrison St, Shawnee, OK 74804 Phone: 405-395-5655

Dr. Stephen Eugene Trotter, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3315 Kethley Rd, Shawnee, OK 74804 Phone: 405-273-5801    Fax: 405-878-3794

News Archive

Low testosterone means men may die young

A new study suggests that men with low levels of testosterone are more likely to die young; they apparently have a 33% increased risk of death over an 18-year period than those with higher levels.

BioCurex reports first set of results supporting RECAF blood test for monitoring cancer therapy

BioCurex Inc. today announced its first set of results supporting the use of the BioCurex RECAF blood test to monitor cancer therapy. The test included samples from 27 human patients with early stages of breast cancer that were tested before and after surgery. As a control, 15 samples from healthy individuals were also tested.

USPTO issues two new patents for EKR Therapeutics' RTU Cardene I.V. Premixed Injection

EKR Therapeutics, Inc., a specialty pharmaceutical company focused on commercializing acute-care hospital products, today announced that the US Patent and Trademark Office has issued two new patents covering methods of treatment and methods of preparation for the Company's Ready-to-Use (RTU) Cardene® I.V. (nicardipine hydrochloride) Premixed Injection.

Novel compound shows promise as potential treatment for acute myeloid leukemia

A novel compound has shown promise in preclinical studies as a treatment for acute myeloid leukemia, more than doubling median days of survival even in a drug-resistant form of the disease.

GOP states struggling with Medicaid expansion issues

Meanwhile, McClatchy News reports that higher rates of mental illness and substance abuse among the newly enrolled will be a problem because there aren't enough therapists who accept Medicaid patients. Medicaid expansion developments in New Hampshire, North Dakota, Wyoming and Virginia are also covered.

Read more Medical News

› Verified 2 days ago